TMS Co., Ltd. (4891.T)
JPY 152.0
(-3.8%)
JPY 152.0
(-3.8%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -937 Million JPY | -396.64% |
| 2022 | -854.87 Million JPY | -115.05% |
| 2021 | 1.08 Billion JPY | 272.13% |
| 2020 | -717.89 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -220 Million JPY | 41.01% |
| 2024 Q2 | -228.98 Million JPY | -3.38% |
| 2023 Q1 | -151.76 Million JPY | -41.13% |
| 2023 Q4 | -361.05 Million JPY | -63.08% |
| 2023 FY | - JPY | -396.64% |
| 2023 Q2 | -193.34 Million JPY | -27.4% |
| 2023 Q3 | -221.39 Million JPY | -14.51% |
| 2022 Q2 | -100 Million JPY | 0.0% |
| 2022 FY | - JPY | -115.05% |
| 2022 Q4 | -107.53 Million JPY | 22.64% |
| 2022 Q3 | -139 Million JPY | -39.0% |
| 2021 FY | - JPY | 272.13% |
| 2020 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 197.798% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -91.956% |
| GNI Group Ltd. | 14.48 Billion JPY | 106.467% |
| Linical Co., Ltd. | 1.24 Billion JPY | 175.126% |
| Trans Genic Inc. | 240.95 Million JPY | 488.874% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 30.892% |
| Soiken Holdings Inc. | -583.2 Million JPY | -60.664% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -55.366% |
| AnGes, Inc. | -8.86 Billion JPY | 89.424% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 27.11% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 87.336% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 831.42% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -8.575% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 14.177% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1846.473% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -20.811% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -738.096% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 22.673% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 32.142% |
| PeptiDream Inc. | 7.37 Billion JPY | 112.703% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 51.443% |
| Ribomic Inc. | -1.01 Billion JPY | 7.459% |
| SanBio Company Limited | -4.52 Billion JPY | 79.293% |
| Healios K.K. | -3 Billion JPY | 68.839% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 19.625% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 32.738% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 33.167% |
| StemRIM | -2.03 Billion JPY | 53.888% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 171.722% |
| FunPep Company Limited | -952 Million JPY | 1.576% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -5.428% |
| Stella Pharma Corporation | -723.85 Million JPY | -29.446% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -20.842% |
| Cuorips Inc. | -518 Million JPY | -80.888% |
| K Pharma,Inc. | 366.05 Million JPY | 355.97% |
| Takara Bio Inc. | 8.02 Billion JPY | 111.677% |
| ReproCELL Incorporated | 8.24 Million JPY | 11464.463% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1165.523% |
| StemCell Institute Inc. | 534.35 Million JPY | 275.352% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 482.74% |
| CellSeed Inc. | -836.51 Million JPY | -12.012% |